ENGQF Stock Quote & Alerts | Stock Alarm Pro

No data available

Want to monitor ENGQF?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

No company information available

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

Key Statistics

About

News

Intel: Big Day

DexCom Stock Declines Following Strong Preliminary Q4 Results

Here is Why Growth Investors Should Buy Universal Health Services (UHS) Now

3 Reasons Growth Investors Will Love Global Payments (GPN)

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Musk and Ryanair CEO clash over cost of Starlink Wi-Fi on planes

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

Can IREN's Vertically Integrated AI Cloud Platform Lift Profitability?

IREN or HUT: Which Bitcoin Infrastructure Stock Should You Bet On?

Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Rebounds As Traders Focus On Supply Risks

Are Early-Season Metrics Signaling Challenges for Vail Resorts?

Genmab's blood cancer drug fails main goal in late-stage study

Federal Signal Completes Acquisition of Mega Corp.

Incyte: Buy For The Turnaround, Stay For The Pipeline

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

International oil companies push for quick reforms in Venezuela to give them control over oil exports

Reasons Why You Should Retain MARA Stock in Your Portfolio

Why Clorox Stock Remains Worth Holding in Your Portfolio Now?

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Explore More

Intel: Big Day

DexCom Stock Declines Following Strong Preliminary Q4 Results

Here is Why Growth Investors Should Buy Universal Health Services (UHS) Now

3 Reasons Growth Investors Will Love Global Payments (GPN)

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Musk and Ryanair CEO clash over cost of Starlink Wi-Fi on planes

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

Can IREN's Vertically Integrated AI Cloud Platform Lift Profitability?

IREN or HUT: Which Bitcoin Infrastructure Stock Should You Bet On?

Natural Gas, WTI Oil, Brent Oil Forecasts – Oil Rebounds As Traders Focus On Supply Risks

Are Early-Season Metrics Signaling Challenges for Vail Resorts?

Genmab's blood cancer drug fails main goal in late-stage study

Federal Signal Completes Acquisition of Mega Corp.

Incyte: Buy For The Turnaround, Stay For The Pipeline

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

International oil companies push for quick reforms in Venezuela to give them control over oil exports

Reasons Why You Should Retain MARA Stock in Your Portfolio

Why Clorox Stock Remains Worth Holding in Your Portfolio Now?

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)